Practice Contact Information
203 Lothrop Street
Web Site: http://www.upmc.com/Services/ear-nose-throat/Pages/default.aspx
Areas of Interest in Head and Neck Surgery
Head and Neck Surgeon, Radiation Oncologist
Robert L. Ferris, MD, PhD, FACS graduated with honors and distinction from the University of North Carolina at Chapel Hill. He completed his MD/PhD in immunology, and residency training in Otolaryngology/Head and Neck Surgery at Johns Hopkins, focused on head and neck oncologic surgery. Dr. Ferris then moved to the University of Pittsburgh as Assistant Professor of Otolaryngology and of Immunology.Dr. Ferris serves in the American Head and Neck Society (AHNS) and is co-Chair of the Eastern Cooperative Oncology Group (ECOG) Head and Neck Committee. He serves as a permanent member of the NIH Cancer Biomarkers study section, on the Editorial Boards of the Journal of Clinical Oncology and Clinical Cancer Research, as Section Editor for head and neck diseases for Cancer, and Associate Editor for Head and Neck and Oral Oncology. In 2008 he was inducted into the American Society for Clinical Investigation (ASCI). Dr. Ferris has published over 170 peer-reviewed scientific and clinical/translational manuscripts, co-authored numerous book chapters and co-edited two books.In 2005, Dr. Ferris became Chief of the Division of Head and Neck Surgery and Director of the Fellowship in Advanced Head and Neck Oncologic Surgery. In 2006, he was promoted to Associate Professor (with Tenure), and in 2007 became Co-Leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute (UPCI). In 2008, Dr. Ferris was named Vice-Chair for Clinical Operations of the Department of Otolaryngology, and is currently the UPMC Endowed Professor of Otolaryngology/Head and Neck Surgery, of Radiation Oncology, and of Immunology. He was recently named Associate Director for Translational Research at the University of Pittsburgh Cancer Institute.As a head and neck surgical oncologist and basic/translational cancer immunologist, his laboratory is focused in reversal of immune escape in cancers and immunotherapy using monoclonal antibodies and cellular vaccines. This research focuses heavily on running phase I and II clinical trials translating novel immunologic agents into the clinic, as well as correlative studies of immune markers in the serum and tumor microenvironment. Molecular genetic biomarkers in thyroid nodules are also being used to personalize perioperative treatment decisions by surgeons. His group is currently investigating immunosuppressive effects which inhibit clinical activity of therapeutic mAb, including cetuximab, checkpoint receptor expression on tumor infiltrating lymphocytes and immune escape mechanisms in HPV+ patients. Dr. Ferris is leading a large national randomized trial (ECOG 3311) testing the feasibility and RT dose-deintensification strategy after transoral surgery for HPV+ oropharyngeal cancer.